The popularity of GLP-1 drugs such as Wegovy and Ozempic has led analysts to speculate that food companies that make fatty or salty snacks or processed food will lose ground as consumers opt for lower-calorie choices. Many makers of snacks, food packaging and other products rocked by the weight-loss-drug phenomenon have worked in recent weeks to calm investors' fears about the medications' potential impact on their bottom line. The selloff is overdone, the Bernstein analysts wrote. If GLP-1 drug use climbs to about 10% of U.S. adults in the next five years, from about 1% today, that could trigger a 2.5% reduction in calories consumed, for an annual food volume headwind of about 0.5% per year, according to the report. Kraft Heinz is relatively well positioned for the GLP-1 drug wave, the Bernstein analysts wrote, given its protein-heavy portfolio. The analysts had a $40 price target for the stock.